Abstract
Serotonin (5-HT) exerts its diverse physiological and pharmacological effects through the activation of multiple receptor subtypes. One of the newest members of this family is the 5-HT7 receptor. Increasing investigations on this receptor are currently undertaken to highlight its physiological and physiopathological significance. With the development of selective 5-HT7 receptor ligands, preclinical studies have started to elucidate the functions of this receptor subtype in more details. Hence, growing body of evidence suggests that the 5-HT7 receptor is involved in biological processes such as circadian rhythm and thermoregulation, in addition to disorders in which disturbances of the latter are considered to be an important contributing factor. Moreover, preclinical data support the use of 5-HT7 receptor antagonism as a promising mechanism for the treatment of several dysfunctions such as cognitive deficits and, importantly, have also unveiled anxiolytic and antidepressant-like properties. In this review, we will report major advances in the discovery of 5-HT7 receptor roles, with special emphasis on the potential application of their antagonists as novel anxiolytic and antidepressant drugs.
Keywords: Serotonin, 5-HT7 receptors, circadian rhythm, thermoregulation, migraine, schizophrenia, anxiety, depression
Current Drug Targets
Title: Therapeutic Potential of 5-HT7 Receptors in Mood Disorders
Volume: 10 Issue: 11
Author(s): Ouissame Mnie-Filali, Laura Lambas-Senas, Helene Scarna and Nasser Haddjeri
Affiliation:
Keywords: Serotonin, 5-HT7 receptors, circadian rhythm, thermoregulation, migraine, schizophrenia, anxiety, depression
Abstract: Serotonin (5-HT) exerts its diverse physiological and pharmacological effects through the activation of multiple receptor subtypes. One of the newest members of this family is the 5-HT7 receptor. Increasing investigations on this receptor are currently undertaken to highlight its physiological and physiopathological significance. With the development of selective 5-HT7 receptor ligands, preclinical studies have started to elucidate the functions of this receptor subtype in more details. Hence, growing body of evidence suggests that the 5-HT7 receptor is involved in biological processes such as circadian rhythm and thermoregulation, in addition to disorders in which disturbances of the latter are considered to be an important contributing factor. Moreover, preclinical data support the use of 5-HT7 receptor antagonism as a promising mechanism for the treatment of several dysfunctions such as cognitive deficits and, importantly, have also unveiled anxiolytic and antidepressant-like properties. In this review, we will report major advances in the discovery of 5-HT7 receptor roles, with special emphasis on the potential application of their antagonists as novel anxiolytic and antidepressant drugs.
Export Options
About this article
Cite this article as:
Mnie-Filali Ouissame, Lambas-Senas Laura, Scarna Helene and Haddjeri Nasser, Therapeutic Potential of 5-HT7 Receptors in Mood Disorders, Current Drug Targets 2009; 10 (11) . https://dx.doi.org/10.2174/138945009789735129
DOI https://dx.doi.org/10.2174/138945009789735129 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging Mitochondria: The Common Upstream Driver of Amyloid-β and Tau Pathology in Alzheimers Disease
Current Alzheimer Research Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Investigating <i>Bacopa monnieri L.</i> Therapeutic Potential for the Treatment of Neurological Diseases
Current Pharmaceutical Design GqPCR-mediated Signalling in the Spotlight: From Visualization Towards Dissection and Quantification
Current Pharmaceutical Biotechnology PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Neuroleptic Malignant Syndrome: A Pilot Study on Psychiatric Inpatients in Iran
Current Psychopharmacology Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Cisternal Sustained Release Dihydropyridines for Subarachnoid Hemorrhage
Current Neurovascular Research The Role of Innate Immune System Receptors in Epilepsy Research
CNS & Neurological Disorders - Drug Targets Pseudomonas aeruginosa Invades Human Aortic Endothelial Cells and Induces Cell Damage in vitro
Cardiovascular & Hematological Disorders-Drug Targets Anesthesia Issues in Central Nervous System Disorders
Current Aging Science AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Suicide Gene Therapy Mediated by the Herpes Simplex Virus Thymidine Kinase Gene / Ganciclovir System: Fifteen Years of Application
Current Gene Therapy Host Immune Responses to Aeromonas Virulence Factors
Current Immunology Reviews (Discontinued) Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals Long-Term CD4 Cell Count Recovery among Thai Naive HIV-Infected Patients Initiating HAART at Low CD4 Cell Count
Current HIV Research Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology Disentangling the Intricacies of Migraine: A Review
CNS & Neurological Disorders - Drug Targets